Roflumilast (Daxas) for chronic obstructive pulmonary disease
|
|
- Vernon Ramsey
- 5 years ago
- Views:
Transcription
1 Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes. The Research Programme is part of the National Institute for Health Research
2 Roflumilast (Daxas) for chronic obstructive pulmonary disease Target group Chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations maintenance therapy. Technology description Roflumilast (Daxas) is a long-acting selective phosphodiesterase-4 (PDE4) inhibitor which relieves the underlying symptoms of COPD through an anti-inflammatory effect. It acts by inhibition of synthesis of leukotriene B4 and reactive oxygen species in neutrophils, as well as inhibition of TNF-α release by mononuclear cells. Roflumilast also inhibits T-cell proliferation, cytokine production, and cell infiltration of the lungs. Roflumilast is administered orally at 500µg Innovation and/or advantages Roflumilast offers a novel mechanism of action as a first in class selective PDE4 inhibitor for COPD. In clinical trials of patients with COPD, it has been shown to improve lung function and reduce exacerbations. Developer Nycomed. Availability, launch or marketing dates, and licensing plans: Phase III clinical trials completed. NHS or Government priority area: This topic is relevant to The National Service Framework for Chronic Obstructive Pulmonary Disease (in development). Relevant guidance NICE clinical guideline. Chronic obstructive pulmonary disease - Management of chronic obstructive pulmonary disease in adults in primary and secondary care Update expected June NICE interventional procedure guidance. Lung reduction volume surgery for advanced emphysema: guidance NICE service guideline. Assisted-discharge service for patients with COPD Clinical Knowledge Summaries. Chronic obstructive pulmonary disease. Care guideline British Thoracic Society. Intermediate care - Hospital-at-Home in chronic obstructive pulmonary disease British Thoracic Society. Current best practice for nebuliser treatment Review expected January American Thoracic Society/European Respiratory Society. Statement on pulmonary rehabilitation American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients with COPD Review expected June
3 Clinical need and burden of disease COPD is a condition characterised by airflow obstruction a that is not fully reversible. The airflow obstruction is due to a combination of airway and parenchymal damage, and is usually progressive. COPD is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Other factors, particularly occupational exposures, may also contribute to its development 1. Significant airflow obstruction may be present before the individual is aware of it. Common symptoms are breathlessness, cough, sputum, wheeze and chest tightness. COPD is a leading cause of morbidity and mortality in the UK. The number of patients on Quality and Outcomes Framework (QOF) disease registers with COPD was approximately 800,000 in the period 2007/08 with an unadjusted prevalence of 1.5% of all patients registered with a general practitioner in England 9. In 2006/07 there were 115,598 admissions to hospital with a primary diagnosis of COPD and 195,468 finished consultant episodes (ICD J40-J44; J47). Of the admissions, 105,266 (91%) were emergencies, which represented 0.8% of all emergency medical admissions to hospital. COPD accounted for 920,167 in-patient bed days, which represented almost 2% of all NHS in-patient bed days 10. There were 24,204 registered deaths from COPD in England and Wales in 2006, 90% of these being in the 65 and over age group 11. Existing comparators and treatments The NICE guideline 1 recommends the following treatment and support options for management of patients with stable COPD: Smoking cessation. Inhaled bronchodilator therapy: Short-acting beta 2 agonist, e.g. salbutamol. Short-acting antimuscarinic, e.g. ipratropium. Long-acting beta 2 agonist, e.g. salmeterol. Long-acting antimuscarinic, e.g. tiotropium. Theophylline - slow-release formulation. Corticosteroids: Inhaled corticosteroid, e.g. beclometasone dipropionate not licensed for use alone in COPD. Oral corticosteroid, e.g. prednisolone not recommended. Combination of the above. Efficacy and safety Trial Roflumilast 250µg, 500µg vs placebo; phase III. NCT ; roflumilast vs placebo, phase III. Roflumilast 500µg vs placebo. Sponsor Altana Pharma. Altana Pharma. Altana Pharma. Status Published 12. Published 13. Published 14. Location EU (inc UK), USA, Canada and other countries. EU (inc UK), Canada and Germany. other countries. Design Randomised, controlled, double-blind. Randomised, controlled, double-blind. Randomised, controlled, double-blind, crossover. Participants n=1,157; age >40 years; n=1,513; age 40 years; n=38; age years; a Airflow obstruction is defined as a reduced FEV 1 (forced expiratory volume in 1 second) and a reduced FEV 1 /FVC ratio (where FVC is forced vital capacity), such that FEV 1 is less than 80% predicted and FEV 1 /FVC is less than
4 and schedule smokers; postbronchodilator FEV 1 /FVC ratio 70% and FEV % predicted normal; FEV 1 reversibility of <12% and/or <200ml; stable concomitant and rescue short-acting bronchodilators allowed. Randomised to roflumilast 250µg, 500µg or placebo smokers; postbronchodilator FEV 1 /FVC ratio 70% and FEV 1 50% predicted normal; FEV 1 reversibility of 15% and/or 200ml. Inhaled corticosteroids or stable short-acting anticholinergics and rescue short-acting bronchodilators allowed. Randomised to roflumilast 500µg or placebo smokers; pre-bronchodilator post-bronchodilator FEV % predicted normal; FEV 1 reversibility of <12% or <200ml; sputum neutrophilia ( 45% nonsquamous cells), no exacerbation or upper respiratory tract infection (URTI) for 4 weeks; stable concomitant short-acting bronchodilators allowed. Randomised to roflumilast 500µg or placebo once daily for 4 weeks. Follow-up 24 weeks treatment period. 52 weeks treatment period. Two treatment periods of 4 weeks with a washout period of 4-6 weeks between. Primary Secondary Key results Adverse effects Trial Post-bronchodilator FEV 1 and St. George s Respiratory Questionnaire (SGRQ) total score. Pre and post-bronchodilator pulmonary function variables; COPD exacerbations. For roflumilast 250µg, 500µg and placebo respectively: post-bronchodilator FEV 1 improvement (SD): +74ml (+/-18) and + 97ml (+/- 18) p<0.001; mean exacerbations per patient 1.03, 0.75 and 1.13; change in total SGRQ score: -3.4, units and -1.8 units (both p-values <0.0001). Study withdrawal due to exacerbation or serious adverse events was similar between groups. Post-bronchodilator FEV 1, moderate to severe exacerbation rate. AURA (124), NCT ; roflumilast vs placebo; COPD and chronic bronchitis; phase III. SGRQ; pulmonary function; quality of life; safety. For roflumilast and placebo respectively: post-bronchodilator FEV 1 (SE): 39ml (+/-12ml) p=0.001; mean moderate or severe exacerbations per patient 0.86 and 0.92; change in total SGRQ score: -1.7 and -2.0 units p= Diarrhoea, nausea, headache. Percentage of sputum neutrophils. FEV 1, sputum neutrophils and other inflammatory cells, markers of activation of inflammatory cells and microvascular leakage in sputum. Significant reduction in neutrophils and eosinophils in sputum vs. placebo % (p=0.002) vs 50% (p<0.001). Inflammatory markers significantly reduced by roflumilast compared with placebo. Post-bronchodilator FEV 1 improved significantly with roflumilast: mean difference vs placebo ml (p=0.018). Diarrhoea, headache. HERMES (125) b, NCT ; roflumilast vs placebo; COPD and chronic bronchitis; phase III. Sponsor Nycomed. Nycomed. Status Completed, unpublished. Completed, unpublished. Location EU (inc UK), USA, Canada and other countries. EU (inc UK), USA, Canada and other countries. Design Randomised, controlled, double-blind. Randomised, controlled, double-blind. 4
5 Participants and schedule n=1,523; age 40 years; smokers; concomitant long-acting beta agonists (LABA) or short-acting anticholinergics allowed; at least 1 moderate and/or severe COPD exacerbation in last year; postbronchodilator FEV 1 50% of predicted normal value; total cough and sputum score 14. Randomised to roflumilast 500µg or placebo n=1,568; age 40 years; smokers; concomitant LABA or short-acting anticholinergics allowed; at least 1 moderate and/or severe documented COPD exacerbation in last year; postbronchodilator FEV 1 50% of predicted normal value; total cough and sputum score 14. Randomised to roflumilast 500µg or placebo Follow-up 52 weeks treatment period. 52 weeks treatment period. Primary Pre-bronchodilator FEV 1 ; COPD exacerbations. Pre-bronchodilator FEV 1 ; COPD exacerbations. Secondary Expected reporting date Trial Post-bronchodilator FEV 1 ; mortality time to death due to any reason; C-reactive protein (CRP); transition dyspnoea indices (TDI) focal score. Autumn Autumn EOS (127), NCT ; roflumilast vs placebo; COPD; phase III. Post-bronchodilator FEV 1 ; mortality time to death due to any reason; CRP; TDI focal score. HELIOS (128), NCT ; roflumilast vs placebo; COPD and chronic bronchitis; phase III. Sponsor Nycomed. Nycomed. Status Completed, unpublished 15. Completed, unpublished 15. Location EU (inc UK), Canada and South Africa. EU (inc UK), Canada and South Africa. Design Randomised, controlled, double-blind. Randomised, controlled, double-blind. Participants and schedule n=933; age >40 years; smokers; postbronchodilator FEV 1 between 40% and 70% of predicted normal; FEV 1 reversibility of 12% or 200ml; no recent COPD exacerbation. Randomised to roflumilast 500µg or placebo once daily; maintenance salmeterol 50µg twice daily. n=743; age >40 years; smokers; pre-treated with tiotropium for 3 months; postbronchodilator FEV 1 between 40% and 70% of predicted normal value; FEV 1 reversibility of 12% or 200ml recent COPD exacerbation. Randomised to roflumilast 500µg or placebo once daily; maintenance tiotropium 18µg Follow-up 24 weeks treatment period. 24 weeks treatment period. Primary Pre-bronchodilator FEV 1. Pre-bronchodilator FEV 1. s Secondary s Mild, moderate or severe COPD exacerbations; mean TDI focal score; shortness of breath questionnaire (SOBQ); spirometry parameters; CRP; cough and sputum. Post-bronchodilator FEV 1 ; moderate or severe COPD exacerbations; further spirometry parameters; CRP; cough and sputum. Key results Met primary endpoints. Met primary endpoints. Expected Autumn Autumn reporting date 5
6 Estimated cost and cost impact The cost of roflumilast is not yet known. The annual costs of licensed therapies for COPD are: Drug Dose Annual cost 16 Salmeterol (Serevent Accuhaler) 50µg twice daily 356 Tiotropium (Spiriva HandiHaler) 18µg once daily 451 Potential or intended impact speculative Patients Reduced morbidity Quicker, earlier or more accurate diagnosis or identification of disease Reduced mortality or increased length of survival Other: Improved quality of life for patients and/or carers: with once daily dosing None identified Services Increased use Service reorganisation required Staff or training required Decreased use: if length of stay and referrals reduced. Costs Increased unit cost compared to alternative New costs: References Other: Increased costs: more patients coming for treatment Savings: if exacerbations reduced. None identified Increased costs: capital investment needed Other: Unknown comparative cost 1 National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease - Management of chronic obstructive pulmonary disease in adults in primary and secondary care. Clinical guideline CG12. London: NICE; February National Institute for Health and Clinical Excellence. Lung reduction volume surgery for advanced emphysema: guidance. Interventional procedure guidance IPG114. London: NICE; February National Institute for Health and Clinical Excellence. Assisted-discharge service for patients with COPD. London: NICE; October Clinical Knowledge Summaries. Chronic obstructive pulmonary disease. Care guideline. August Accessed 27 February Stevenson R, Angus R, Blanchard M et al. Intermediate care - Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline. Thorax 2007;62(3): British Thoracic Society. Current best practice for nebuliser treatment. Care guideline. April Nici L, Donner C, Wouters E et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. American Journal of Respiratory and Critical Care Medicine 2006;173(12): American Thoracic Society/European Respiratory Society. Standards for the diagnosis and management of patients with COPD. June The Information Centre for Health and Social Care the Quality and Outcomes Framework. National level QOF tables 2007/08 prevalence /08/data-tables Accessed 4 March NHS. Hospital episode statistics. NHS England HES data Office for National Statistics. Mortality statistics: Deaths registered in 2006, DR_06, Newport: Office for National Statistics,
7 12 Rabe KF, Bateman ED, D O'Donnell et al. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366(9485): Calverley PM, Sanchez-Toril F, McIvor A et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 2007;176(2): Grootendorst DC, Gauw SA, Verhoosel RM et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007;62: Press release. Nycomed s Daxas shows encouraging preliminary results. Accessed 29 June British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. BMJ Group and RPS Publishing. London; March The National Institute for Health Research Research Programme is funded by the Department of Health. The views expressed in this publication are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health The, Department of Public Health and Epidemiology University of Birmingham, Edgbaston, Birmingham, B15 2TT, England Tel: +44 (0) Fax +44 (0)
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationRoflumilast for the treatment of respiratory disease: review of the Phase II and III trials
Roflumilast for the treatment of respiratory disease: review of the Phase II and trials Clin. Invest. (2011) 1(10), 1413 1419 Roflumilast (Daxas [EU], Daliresp [USA]) is the first phospho diesterase 4
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationRe-Submission. roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd. Published 11 September
Re-Submission roflumilast, 500 microgram, film-coated tablet (Daxas ) SMC No 635/10 AstraZeneca UK Ltd 4 August 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationRoflumilast: Οι κλινικές μελέτες
Roflumilast: Οι κλινικές μελέτες Επαμεινώνδας Ν. Κοσμάς Δ/ντής Πνευμονολογικού Τμήματος Νοσοκομείου Metropolitan PDE4 PLAYS AN IMPORTANT ROLE IN INFLAMMATION PDE4 inhibition P P P PDE4 P Adapted from Rabe
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationInsulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children
Insulin glulisine (Apidra) for type 1 diabetes mellitus in adolescents and children December 2008 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Methylnaltrexone (MOA-728) for postoperative ileus. April 2008
(MOA-728) for postoperative ileus April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
DRAFT NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder. Reference number: 938 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder Reference number: 938 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationNational Horizon Scanning Centre. Ampligen for chronic fatigue syndrome. December 2007
Ampligen for chronic fatigue syndrome December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationCEDAC FINAL RECOMMENDATION
CEDAC FINAL RECOMMENDATION ROFLUMILAST (Daxas Nycomed Canada Inc.) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationRilonacept for cryopyrin associated periodic syndromes
Rilonacept for cryopyrin associated periodic syndromes August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationNational Horizon Scanning Centre. GV1001 for advanced and/or metastatic pancreatic cancer. April 2008
GV1001 for advanced and/or metastatic pancreatic cancer April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationNational Horizon Scanning Centre. Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids.
Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids May 2008 This technology summary is based on information available at the time of research and a limited
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationRoflumilast for the management of severe chronic obstructive pulmonary disease
Roflumilast for the management of severe chronic obstructive pulmonary disease Issued: January 2012 www.nice.org.uk/ta244 NHS Evidence has accredited the process used by the Centre for Health Technology
More informationRiociguat for chronic thromboembolic pulmonary hypertension
Riociguat for chronic thromboembolic pulmonary hypertension This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationRoflumilast for the management of severe chronic obstructive pulmonary disease
Roflumilast for the management of severe chronic obstructive pulmonary disease Issued: January 2012 guidance.nice.org.uk/ta244 NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationNational Horizon Scanning Centre. Decitabine (Dacogen) for myelodysplastic syndrome. April 2008
Decitabine (Dacogen) for myelodysplastic syndrome April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be
More informationCommissioning for Better Outcomes in COPD
Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationHorizon Scanning Technology Summary. Adalimumab (Humira) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Adalimumab (Humira) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationRoflumilast with long-acting b 2 -agonists for COPD: influence of exacerbation history
Eur Respir J 211; 3: 553 56 DOI: 1.113/9319.1771 CopyrightßERS 211 with long-acting b 2 -agonists for COPD: influence of exacerbation history E.D. Bateman*, K.F. Rabe #,", P.M.A. Calverley +, U.M. Goehring
More informationProvider Respiratory Inservice
Provider Respiratory Inservice 2 Welcome Opening Remarks We will cover: Definition of Asthma & COPD Evidence based guidelines for diagnosis, evaluation, and management of asthma Evidence based guidelines
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationUNDERSTANDING COPD MEDIA BACKGROUNDER
UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationChronic Obstructive Pulmonary Disease (COPD) Measures Document
Chronic Obstructive Pulmonary Disease (COPD) Measures Document COPD Version: 3 - covering patients discharged between 01/10/2017 and present. Programme Lead: Jo Higgins Clinical Lead: Dr Paul Albert Number
More informationThis is the publisher s version. This version is defined in the NISO recommended practice RP
Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationRoflumilast for Management of Chronic Obstructive Pulmonary Disease
Roflumilast for Management of Chronic Obstructive Pulmonary Disease Submission to National Institute for Health and Clinical Excellence Single Technology Appraisal (STA) May 2011 Manufacturer MSD Ltd 1
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationEribulin for locally advanced or metastatic breast cancer third line; monotherapy
Eribulin for locally advanced or metastatic breast cancer third line; monotherapy April 2009 This technology summary is based on information available at the time of research and a limited literature search.
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationCOPD. Helen Suen & Lexi Smith
COPD Helen Suen & Lexi Smith What is COPD? Chronic obstructive pulmonary disease: a non reversible, long term lung disease Characterized by progressively limited airflow and an inability to perform full
More information